Evidence map›Paper›PMID 19110618›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2009

Genetic modification of human hematopoietic cells: preclinical optimization of oncoretroviral-mediated gene transfer for clinical trials.

Tulin Budak-Alpdogan, Isabelle Rivière

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tulin Budak-AlpdoganDepartment of Medicine, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA.
Isabelle Rivière

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
TUMORICIDAL FUNCTIONS OF T LYMPHOCYTES IN PSMA TUMORSP01CA059350 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI O'REILLY, RICHARD JOHN · 1992 to 2012
$21.4M
TREATMENT OF CANCER PATIENTS WITH THYMIC FACTORSP01CA033049 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI DIVGI, CHAITANYA R. · 1985 to 2009
$19.8M
NCI NIH HHS P01 CA-033049NCI NIH HHS P01 CA033049NCI NIH HHS P01 CA-059350NCI NIH HHS P01 CA059350NCI NIH HHS P30 CA-008748NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

This chapter provides information about the oncoretroviral transduction of human hematopoietic stem/ progenitor cells under clinically applicable conditions. We describe in detail a short -60 h transduction protocol which consistently yields transduction efficiencies in the range of 30-50% with five different oncoretroviral vectors. We discuss a number of parameters that affect transduction efficiency, including the oncoretroviral vector characteristics, the vector stock collection, the source of CD34+ cells and transduction conditions.

Indexed as

Genetic VectorsGene Transfer TechniquesAntigens, CD34Cells, CulturedCulture Media, Serum-FreeHematopoietic Stem CellsHumansPolymerase Chain ReactionRetroviridaeTransduction, GeneticAntigens, CD34Culture Media, Serum-Free

Identifiers

PMID19110618
PMCPMC4360985

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.